Clinical trials: Cholesterol; Metabolic Disorder
Cardiovascular Diseases, Prevention
Cardiovascular Health Promotion Among African-Americans by FAITH!
Given the importance of healthy lifestyle practices to cardiovascular disease (CVD) prevention and the utility of church-based interventions in African-American adults, the investigators developed a theory-informed…
- Conditions
- Cardiovascular Diseases, Prevention, Physical Activity, Diet Modification
- Trial name
- FAITH! (NCT03084822)
- Testing
- FAITH! App digital intervention
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Epilepsy, Dyslipidemia
Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet
Ketogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications.
- Trial name
- NCT06369571
- Testing
- Atorvastatin 10mg, Modification of dietary fat composition
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Cardiovascular Diseases
Evaluating Electrocardiogram (ECG) Abnormalities From Young Adulthood Through Middle Age
An electrocardiogram (ECG) is a test that evaluates the electrical activity of the heart and can be used to detect heart problems.
- Trial name
- CARDIA ECG (NCT00556751)
- Where
- United States
- Volunteers
- 5,115 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemias, LDL Hyperlipoproteinemia
Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study
Red yeast rice is a source of active compounds in reducing LDL levels with practically no side effects. Molval Fort is a natural product available in the Lebanese market with a combination of red yeast rice extracts, EPA/DHA and…
- Trial name
- NCT03607383
- Testing
- Red Rice Yeast Extract, Statin
- Where
- Lebanon
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Saint-Joseph University
Dyslipidemia
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.
- Trial name
- NCT00504829
- Testing
- LCP-AtorFen, atorvastatin, fenofibrate
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Veloxis Pharmaceuticals
Acid Lipase Deficiency, Acid Cholesteryl Ester Hydrolase Deficiency, Wolman Type
Biomarker for Wolman Disease (BioWolman)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Wolman disease blood (plasma)
- Conditions
- Acid Lipase Deficiency, Acid Cholesteryl Ester Hydrolase Deficiency, Wolman Type, Cholesterol Ester Storage Disease
- Trial name
- BioWolman (NCT02383641)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
A multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus atorvastatin in elderly patients with high cholesterol at high or moderately high risk for coronary heart disease.
- Trial name
- NCT00535405
- Testing
- Atorvastatin 10 mg, Ezetimibe 10 mg/simvastatin 20 mg, Atorvastatin 20 mg
- Volunteers
- 1,289 people
- Sponsor
- Organon and Co
Type II Hyperlipidemia
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C) in people with abnormal…
- Trial name
- NCT01388816
- Where
- 12 sites in Italy, Poland and 1 more
- Volunteers
- 176 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Fed
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding…
- Trial name
- NCT01827878
- Testing
- Lisinopril and Hydrochlorothiazide Tablets (20+25) mg, Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- IPCA Laboratories Ltd.
HIV Infections, Hyperlipidemia
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Treatment of HIV with combination antiretroviral regimens frequently results in the suppression of HIV viral load, significant immune recovery, and delayed disease progression.
- Trial name
- NCT00663234
- Testing
- Atorvastatin
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Dyslipidemia
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
- Trial name
- EBBINGHAUS (NCT02207634)
- Testing
- Evolocumab, Background Statin Therapy
- Where
- 416 sites in United States, Australia and 28 more
- Volunteers
- 1,974 people
- Sponsor
- Amgen
Hyperlipidemia
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from…
- Trial name
- LAPLACE-2 (NCT01763866)
- Testing
- Evolocumab, Ezetimibe, Atorvastatin
- Where
- 244 sites in United States, Australia and 19 more
- Volunteers
- 2,067 people
- Sponsor
- Amgen
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemias, Cardiovascular Diseases
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial…
- Conditions
- Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
- Trial name
- NCT05488431
- Testing
- Bempedoic acid
- Where
- 3 sites in United States
- Volunteers
- 121 people
- Sponsor
- Priscilla Hsue, MD
Prediabetes, Diabetes
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides…
- Conditions
- Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight
- Trial name
- NCT06988462
- Testing
- Bottarga, Comparator
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cambridge Health Alliance
Metabolic Syndrome
Effect of Brown Rice on the Risk Factors for Metabolic Syndrome
The purpose of the study is to determine the effect of consumption of brown rice on the risk factors of metabolic syndrome (MetS) as compared to consumption of white rice.
- Trial name
- NCT02321553
- Testing
- Brown rice, White rice
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Tufts University
Hypercholesterolemia, Coronary Heart Disease
Phytosterols, Ezetimibe, and Cholesterol Metabolism
Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear to have different mechanisms of action.
- Trial name
- Phyteaux-III (NCT00863265)
- Testing
- Ezetimibe, Phytosterols + ezetimibe
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hypercholesterolemia
Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status
To examine whether Docosahexaenoic Acid (DHA) and Docosahexaenoic + Eicosapentaenoic Acids (DHA+EPA) supplementation in addition to National Cholesterol Education Program Step I Diet in Hypercholesterolemic Children increases…
- Trial name
- DHA-RICHOIL (NCT00678067)
- Testing
- Docosahexaenoic acid, Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA), Germ oil
- Volunteers
- 36 people
- Sponsor
- University of Milan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.